(epirubicin HCl)
ELLENCE is available in polypropylene single-dose CYTOSAFE® vials containing 2 mg epirubicin hydrochloride per mL as a sterile, preservative-free, ready-to-use, clear, red solution in the following strengths:
Unit of Sale | Strength |
NDC 0009-5091-01 Carton of 1 Single-dose Vial | 50 mg/25 mL (2 mg/mL) |
NDC 0009-5093-01 Carton of 1 Single-dose Vial | 200 mg/100 mL (2 mg/mL) |
Discard unused portion.
ELLENCE is available in ONCO-TAIN® glass vials containing 2 mg epirubicin hydrochloride per mL as a sterile, preservative-free, ready-to-use, clear, red solution in the following strengths:
Unit of Sale | Strength |
NDC 0009-5091-25 Carton of 1 Single-dose Vial | 50 mg/25 mL (2 mg/mL) |
NDC 0009-5093-10 Carton of 1 Single-dose Vial | 200 mg/100 mL (2 mg/mL) |
ONCO-TAIN® is the vial external protection system.
Discard unused portion.
Store refrigerated between 2°C and 8°C (36°F and 46°F). Do not freeze. Protect from light.
Storage of the solution for injection at refrigerated conditions can result in the formation of a gelled product. This gelled product will return to a slightly viscous to mobile solution after 2 to a maximum of 4 hours equilibration at controlled room temperature (15–25°C). Solution for injection should be used within 24 hours after removal from refrigeration.
ELLENCE is a hazardous drug. Follow applicable special handling and disposal procedures1 [see References (15)].
Additional Resources
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine or vaccine.
Speak with a Pfizer Medical Information Professional regarding your Pfizer medicine or vaccine inquiry.
Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for a Pfizer medicine or a vaccine.
The submission will be reviewed during our standard business hours.
To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this medication, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website to report an adverse event related to a Pfizer medication, please call (800) 438-1985.
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or by calling (800) 332-1088.